Skip to main content
PMC home page
British Journal of Clinical Pharmacology logoLink to British Journal of Clinical Pharmacology
. 1989 Mar;27(3):343–351. doi: 10.1111/j.1365-2125.1989.tb05375.x

Cardiovascular (ECG and systolic time intervals) and anticholinergic effects of repeated doses of femoxetine--a comparison with amitriptyline and placebo in healthy men.

S J Warrington 1, P Turner 1, B K Skrumsager 1
PMCID: PMC1379833  PMID: 2719894

Abstract

1. The cardiovascular and anticholinergic effects of femoxetine and amitriptyline were compared with those of placebo in a double-blind cross-over trial in 12 healthy men. The daily doses administered were therapeutic: 600 mg femoxetine and 150 mg amitriptyline. Duration of treatment with each drug was 13 days. 2. The statistically significant effects on systolic time intervals and ECG comprised a larger decrease of QS2 index during femoxetine than during amitriptyline, and an increase of PEP/LVET ratio and QRS duration by amitriptyline. These results suggest that femoxetine and, to a lesser extent, amitriptyline increase contractility compared with placebo, and amitriptyline, but not femoxetine, causes delay in intracardiac conduction. 3. The effects of amitriptyline on the systolic time intervals are difficult to interpret because of the changes in heart rate and intracardiac electrical conduction caused by the drug. These problems of interpretation are discussed. 4. No significant changes in blood pressure were observed. The heart rate during both femoxetine and amitriptyline periods was significantly faster than during the placebo period, amitriptyline causing a significantly greater increase. 5. Salivary secretion was decreased more by amitriptyline (26%) than by femoxetine (8%), the latter being not significantly different from placebo. Femoxetine tended to increase pupil diameter and amitriptyline to increase accommodation near point, but no visual disturbances were reported on any treatment. Symptoms such as dry mouth, constipation and sedation were significantly less frequently reported during femoxetine than during amitriptyline treatment.

Full text

PDF
347

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Bechgaard E., Lund J. Determination of (+)-(3R), (4S)-3-[(4methoxyphenoxy)methyl]-1-methyl-4-phenylpiperidine hydrochloride (FG 4963) in biological fluids using competition for adsorption to glass. J Chromatogr. 1977 Mar 11;133(1):147–152. doi: 10.1016/s0021-9673(00)89214-6. [DOI] [PubMed] [Google Scholar]
  2. Bryson S. M., Whiting B., Lawrence J. R. Disopyramide serum and pharmacologic effect kinetics applied to the assessment of bioavailability. Br J Clin Pharmacol. 1978 Nov;6(5):409–419. doi: 10.1111/j.1365-2125.1978.tb04605.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  3. Burckhardt D., Raeder E., Müller V., Imhof P., Neubauer H. Cardiovascular effects of tricyclic and tetracyclic antidepressants. JAMA. 1978 Jan 16;239(3):213–216. [PubMed] [Google Scholar]
  4. Burgess C. D., Montgomery S., Wadsworth J., Turner P. Cardiovascular effects of amitriptyline, mianserin, zimelidine and nomifensine in depressed patients. Postgrad Med J. 1979 Oct;55(648):704–708. doi: 10.1136/pgmj.55.648.704. [DOI] [PMC free article] [PubMed] [Google Scholar]
  5. Burgess C. D., Turner P., Wadsworth J. Cardiovascular responses to mianserin hydrochloride: a comparison with tricyclic antidepressant drugs. Br J Clin Pharmacol. 1978;5 (Suppl 1):21S–28S. [PMC free article] [PubMed] [Google Scholar]
  6. Burrows F. G. A Few Illustrative Cases of Diphtheria. Cal State J Med. 1903 Oct;1(11):329–334. [PMC free article] [PubMed] [Google Scholar]
  7. Clemmesen L., Jensen E., Min S. K., Bolwig T. G., Rafaelsen O. J. Salivation after single-doses of the new antidepressants femoxetine, mianserin and citalopram. A cross-over study. Pharmacopsychiatry. 1984 Jul;17(4):126–132. doi: 10.1055/s-2007-1017422. [DOI] [PubMed] [Google Scholar]
  8. Cokkinos D. V., Heimonas E. T., Demopoulos J. N., Harralambakis A., Tsartsalis G., Gardikas C. D. Influence of heart rate increase on uncorrected pre-ejection period/left ventricular ejection time (PEP/LVET) ratio in normal individuals. Br Heart J. 1976 Jul;38(7):683–688. doi: 10.1136/hrt.38.7.683. [DOI] [PMC free article] [PubMed] [Google Scholar]
  9. Dahl L. E., Lundin L., le Fèvre Honoré P., Dencker S. J. Antidepressant effect of femoxetine and desipramine and relationship to the concentration of amine metabolites in cerebrospinal fluid. A double-blind evaluation. Acta Psychiatr Scand. 1982 Jul;66(1):9–17. doi: 10.1111/j.1600-0447.1982.tb00909.x. [DOI] [PubMed] [Google Scholar]
  10. Ghose K., Gupta R., Coppen A., Lund J. Antidepressant evaluation and the pharmacological actions of FG4963 in depressive patients. Eur J Pharmacol. 1977 Mar 7;42(1):31–37. doi: 10.1016/0014-2999(77)90187-x. [DOI] [PubMed] [Google Scholar]
  11. Giardina E. G., Bigger J. T., Jr, Glassman A. H., Perel J. M., Kantor S. J. The electrocardiographic and antiarrhythmic effects of imipramine hydrochloride at therapeutic plasma concentrations. Circulation. 1979 Nov;60(5):1045–1052. doi: 10.1161/01.cir.60.5.1045. [DOI] [PubMed] [Google Scholar]
  12. Glassman A. H., Bigger J. T., Jr Cardiovascular effects of therapeutic doses of tricyclic antidepressants. A review. Arch Gen Psychiatry. 1981 Jul;38(7):815–820. doi: 10.1001/archpsyc.1981.01780320095011. [DOI] [PubMed] [Google Scholar]
  13. Jeppesen K. V., Fledelius H. C. Femoxetine and eye function. A study of possible anticholinergic side effects. Pharmacopsychiatry. 1985 May;18(3):231–234. doi: 10.1055/s-2007-1017371. [DOI] [PubMed] [Google Scholar]
  14. Johnson B. F., Meeran M. K., Frank A., Taylor S. H. Systolic time intervals in measurement of inotropic response to drugs. Br Heart J. 1981 Nov;46(5):513–521. doi: 10.1136/hrt.46.5.513. [DOI] [PMC free article] [PubMed] [Google Scholar]
  15. Kantor S. J., Glassman A. H., Bigger J. T., Jr, Perel J. M., Giardina E. V. The cardiac effects of therapeutic plasma concentrations of imipramine. Am J Psychiatry. 1978 May;135(5):534–538. doi: 10.1176/ajp.135.5.534. [DOI] [PubMed] [Google Scholar]
  16. Kelman A. W., Sumner D. J., Whiting B. Systolic time interval v heart rate regression equations using atropine: reproducibility studies. Br J Clin Pharmacol. 1981 Jul;12(1):15–20. doi: 10.1111/j.1365-2125.1981.tb01849.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  17. Kingsley P. J., Turner P. Class experiment in clinical pharmacology with benzilonium bromide, an anticholinergic drug. Eur J Clin Pharmacol. 1974;7(2):141–143. doi: 10.1007/BF00561329. [DOI] [PubMed] [Google Scholar]
  18. Lassen J. B., Squires R. F., Christensen J. A., Molander L. Neurochemical and pharmacological studies on a new 5HT-uptake inhibitor, FG4963, with potential antidepressant properties. Psychopharmacologia. 1975 Apr 30;42(1):21–26. doi: 10.1007/BF00428820. [DOI] [PubMed] [Google Scholar]
  19. Lund J., Lomholt B., Fabricius J., Christensen J. A., Bechgaard E. Paroxetine: pharmacokinetics, tolerance and depletion of blood 5-HT in man. Acta Pharmacol Toxicol (Copenh) 1979 Apr;44(4):289–295. doi: 10.1111/j.1600-0773.1979.tb02332.x. [DOI] [PubMed] [Google Scholar]
  20. Peet M., Tienari P., Jaskari M. O. A comparison of the cardiac effects of mianserin and amitriptyline in man. Pharmakopsychiatr Neuropsychopharmakol. 1977 Dec;10(6):309–312. doi: 10.1055/s-0028-1094554. [DOI] [PubMed] [Google Scholar]
  21. Spodick D. H. Measurement of cardiac pre-ejaction period. N Engl J Med. 1977 Apr 7;296(14):822–823. doi: 10.1056/nejm197704072961424. [DOI] [PubMed] [Google Scholar]
  22. Staniforth D. H. Systolic time intervals: the effect of stroke volume in healthy young men. Eur J Clin Pharmacol. 1983;24(2):179–183. doi: 10.1007/BF00613814. [DOI] [PubMed] [Google Scholar]
  23. Taylor D. J., Braithwaite R. A. Cardiac effects of tricyclic antidepressant medication. A preliminary study of nortriptyline. Br Heart J. 1978 Sep;40(9):1005–1009. doi: 10.1136/hrt.40.9.1005. [DOI] [PMC free article] [PubMed] [Google Scholar]
  24. Thayssen P., Bjerre M., Kragh-Sørensen P., Møller M., Petersen O. L., Kristensen C. B., Gram L. F. Cardiovascular effect of imipramine and nortriptyline in elderly patients. Psychopharmacology (Berl) 1981;74(4):360–364. doi: 10.1007/BF00432748. [DOI] [PubMed] [Google Scholar]
  25. U'Prichard D. C., Greenberg D. A., Sheehan P. P., Snyder S. H. Tricyclic antidepressants: therapeutic properties and affinity for alpha-noradrenergic receptor binding sites in the brain. Science. 1978 Jan 13;199(4325):197–198. doi: 10.1126/science.202024. [DOI] [PubMed] [Google Scholar]
  26. Veith R. C., Friedel R. O., Bloom V., Bielski R. Electrocardiogram changes and plasma desipramine levels during treatment of depression. Clin Pharmacol Ther. 1980 Jun;27(6):796–802. doi: 10.1038/clpt.1980.113. [DOI] [PubMed] [Google Scholar]
  27. Vohra J., Burrows G. D., Sloman G. Assessment of cardiovascular side effects of therapeutic doses of tricyclic anti-depressant drugs. Aust N Z J Med. 1975 Feb;5(1):7–11. doi: 10.1111/j.1445-5994.1975.tb03247.x. [DOI] [PubMed] [Google Scholar]
  28. Vohra J., Burrows G., Hunt D., Sloman G. The effect of toxic and therapeutic doses of tricyclic antidepressant drugs on intracardiac conduction. Eur J Cardiol. 1975 Oct;3(3):219–227. [PubMed] [Google Scholar]
  29. Weissler A. M., Harris W. S., Schoenfeld C. D. Systolic time intervals in heart failure in man. Circulation. 1968 Feb;37(2):149–159. doi: 10.1161/01.cir.37.2.149. [DOI] [PubMed] [Google Scholar]
  30. Ziegler V. E., Biggs J. T. Electrocardiographic findings in patients undergoing amitriptyline treatment. Dis Nerv Syst. 1977 Sep;38(9):697–699. [PubMed] [Google Scholar]

Articles from British Journal of Clinical Pharmacology are provided here courtesy of British Pharmacological Society

RESOURCES